Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 01, 2016 16:05 ET | Source: Aravive, Inc.

Versartis to Present at the Cowen and Company 36th Annual Health Care Conference

MENLO PARK, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting...
February 18, 2016 16:05 ET | Source: Aravive, Inc.

Versartis Reports Fourth Quarter and Full Year 2015 Financial Results

MENLO PARK, Calif., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting...
February 02, 2016 07:00 ET | Source: Aravive, Inc.

Versartis Reports Confirmatory Top-Line Two-Year Data from Ongoing Extension Study of Somavaratan in GHD Children

Safe and well tolerated over two yearsHeight velocity (HV) in second year comparable to published US rhGH daily dosing data; further confirms Phase 3 dose and scheduleExtremely high rate of...
January 28, 2016 16:05 ET | Source: Aravive, Inc.

Versartis to Host Conference Call to Review Two-Year Top-Line Data From Ongoing Extension Study of Somavaratan

Conference Call and Webcast Featuring Guest Speaker Dr. Bradley Miller Scheduled at 7:30 a.m. ET on February 2, 2016 Management to Participate in the Canaccord Genuity 2016 Rare Disease, BioPharma...
December 16, 2015 13:37 ET | Source: Aravive, Inc.

Versartis’ VRS-317 6-Month Data Published in The Journal of Clinical Endocrinology & Metabolism

MENLO PARK, Calif., Dec. 16, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting...
November 03, 2015 16:15 ET | Source: Aravive, Inc.

Versartis to Present at the Credit Suisse 24th Annual Healthcare Conference

MENLO PARK, Calif., Nov. 3, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form...
October 29, 2015 16:05 ET | Source: Aravive, Inc.

Versartis Reports Third Quarter 2015 Financial Results

MENLO PARK, Calif., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form...
October 01, 2015 08:30 ET | Source: Aravive, Inc.

Versartis Presents Confirmatory 18-Month Data From Ongoing Somavaratan Extension Study at Late-Breaker Session at ESPE Annual Meeting

MENLO PARK, Calif., Oct. 1, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form...
September 18, 2015 08:00 ET | Source: Aravive, Inc.

Versartis Announces Confirmatory 18-Month Data From Ongoing Extension Study of Somavaratan in GHD Children

MENLO PARK, Calif., Sept. 18, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form...
September 10, 2015 08:35 ET | Source: Aravive, Inc.

Versartis Appoints Lars Ekman, MD, PhD, as Global Development Advisor

MENLO PARK, Calif., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form...